Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/130575
| Title: | Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis | Authors: | Pemmaraju, Naveen Mead, Adam J. Somervaille, Tim C. P. McCloskey, James K. Palandri, Francesca Koschmieder, Steffen Lavie, David Leber, Brian Yeh, Su-Peng Gómez Casares, María Teresa Ammatuna, Emanuele Shin, Ho-Jin Kirito, Keita Jourdan, Eric Devos, Timothy Chuah, Hun S. Radinoff, Atanas Bogdanovic, Andrija Moskal, Rastislav Jiang, Qi Chopra, Avijeet S. Papadopoulos, Elektra Potluri, Jalaja Passamonti, Francesco |
UNESCO Clasification: | 32 Ciencias médicas 3209 Farmacología |
Issue Date: | 2023 | Journal: | Blood | Conference: | The 65th ASH Annual Meeting Abstracts | URI: | http://hdl.handle.net/10553/130575 | ISSN: | 0006-4971 | DOI: | 10.1182/blood-2023-173509 | Source: | Blood[ISSN 0006-4971],v. 142 sup. 1, p. 620-624 (Noviembre 2023) |
| Appears in Collections: | Actas de congresos |
WEB OF SCIENCETM
Citations
17
checked on Mar 30, 2025
Page view(s)
40
checked on Nov 9, 2024
Download(s)
54
checked on Nov 9, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.